Department of Hospital Pharmacy, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.
Department of Internal Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.
Br J Clin Pharmacol. 2024 Aug;90(8):1884-1891. doi: 10.1111/bcp.16125. Epub 2024 Jun 7.
Antihypertensive drugs do not qualify as optimal candidates for therapeutic drug monitoring (TDM), given their obvious physiological effect, the absence of a clear relationship between drug concentrations and pharmacodynamic outcomes and their wide therapeutic range. However, since non-adherence is a major challenge in hypertension management, using drug concentrations can be of value to identify non-adherence as a first step towards better blood pressure control. In this article we discuss the key challenges associated with measuring and interpreting antihypertensive drug concentrations that are important when TDM is used to improve non-adherence. Additionally, we elaborate on the role of TDM in optimizing antihypertensive drug treatment besides addressing non-adherence by highlighting its value in specific patient groups with altered pharmacokinetic parameters such as female vs. male or elderly patients.
鉴于降压药物具有明显的生理作用、药物浓度与药效结果之间不存在明确关系且治疗窗较宽,它们不符合治疗药物监测(TDM)的最佳候选药物条件。然而,由于不遵医嘱是高血压管理中的一个主要挑战,因此,使用药物浓度可以作为识别不遵医嘱的一种手段,从而更好地控制血压。本文讨论了在 TDM 用于改善不遵医嘱时,与测量和解释降压药物浓度相关的关键挑战。此外,我们还阐述了 TDM 在优化降压药物治疗方面的作用,除了解决不遵医嘱问题外,还突出了 TDM 在具有改变的药代动力学参数的特定患者群体(如女性与男性或老年患者)中的价值。